Abbott, one of the India’s largest health care companies, have unveiled plans to establish its first nutrition research and development center in the country in collaboration with Syngene, India’s leading contract research organization and also subsidiary of Biocon.
The Abbott Nutrition R&D Center in India will focus on the development of science based, affordable nutrition products for the country and enable the expansion of Abbott’s nutrition product portfolio there. It will focus on development of nutrition products for maternal and child nutrition and diabetes care.
Abbott Selected the largest biotech company in India-Syngene, to provide a science based research and innovation team to work closely with Abbott researchers. More than 50 researchers and scientists will be based at Abbott Nutrition R&D Center in India at Biocon Park, which is expected to open in June 2012.
Biocon is Asia’s leading R&D based Biotechnology Company. It produces anti-diabetic agents like Acarbose, Pioglitazone, Repaglinides and Rosiglitazone. In the biological segment it produces Insulin, Erythropoietin (EPO), Filgrastim (GCSF), Streptokinase and Monoclonal Antibodies. The drug major also produces mycophenolate mofetil, sirolimus and tacrolimus.
Company Name | CMP |
---|---|
Sun Pharma Inds. | 1849.05 |
Dr. Reddys Lab | 1274.25 |
Cipla | 1553.20 |
Lupin | 2184.00 |
Zydus Lifesciences | 1001.85 |
View more.. |